SBIR/STTR Research Award
An immunomodulatory yeast-derived beta glucan as a component of a conjugate
Award amount
$149,450Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOTHERA
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Fungal infections, particularly in immunocompromised patients, are a serious and growing problem. Although antifungal therapeutics have improved greatly, failures and relapse are common. Aspergillus fumigatus is a primary cause of these infections in several patient populations: transplants, leukemics, genetic deficiencies such as chronic granulomatous disease and others, with mortality remaining high. Preventative antifungal vaccines are an attractive, but as yet unrealized, option. The goal of this proposal is to develop a prototype glucan-protein vaccine by conjugating a protein to a particulate -glucan immunomodulator (i.e., WGP), a cell wall component of many pathogenic fungi. Preliminary work using WGP alone or conjugated to a non-specific protein, bovine serum albumin (BSA), indicated that a glucan-protein vaccine was active against Aspergillus and Coccidioides. The work described in this proposal will examine the potential of conjugating a specific, immunodom
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients